Download Pharma and Biotech 2015 in Review, this report from our editorial team EP Vantage, shows that funding for early stage biopharma research dwindled in 2015, as investors shifted their support to more mature companies.
The report offers analysis and expert commentary on M&A deals, venture financing, initial public offerings and FDA approvals in the pharma sector in 2015.
Drug pricing and sustainability issues took the air out of the biotech bubble, leading to the early 2016 market collapse, which negated almost all stock price gains since mid-2014
A shift toward mega investment rounds became evident in the pharma & biotech world
Top-ten, triple digit venture capital raises consumed nearly one quarter of all available funds for development stage biotechs
Pharma & Biotech FDA approvals jumped from an unprecedented 50 in 2014, to 57 in 2015